



Individualizing Therapy and
Optimizing Treatments in

MIS

PROGRAM SYLLABUS

Presented by

SPEAKER NAME, MD

Hospital Name

Date

Jointly provided by Potomac Center for Medical Education and Rockpointe

Supported by an educational grant from EMD Serono



Rockpointe

CONTENTS

Program Overview/Statement of Need	Page 3
Target Audience and Learning Objectives.....	Page 3
CME Statements	Page 4
Disclosures.....	Page 5
Steering Committee.....	Pages 6-7
Faculty.....	Page 8

ADDITIONAL PACKET CONTENTS

Participant Survey and CME Evaluation.....	Front of packet
<i>After filling out the Activity Survey, Post-activity Survey, and CME Evaluation, please separate from packet and return to onsite staff</i>	
Program Slides	
<i>Copy of presentation slides with space for note-taking</i>	

PROGRAM OVERVIEW/STATEMENT OF NEED

The Potomac Center for Medical Education and Rockpointe welcome you to **Individualizing Therapy and Optimizing Treatments in MS**, a CME-certified Neurology Exchange Grand Rounds activity designed to give medical professionals the latest news and information on the management of multiple sclerosis (MS) patients.

The National Multiple Sclerosis Disease Management Consensus Statement recommends continuous use of disease-modifying drug (DMD) therapy, with initiation of a DMD as soon after definitive diagnosis as possible, and to also consider DMD therapy in select high-risk patients with a first attack. This push for earlier diagnosis and earlier initiation of DMD therapy has made MS management increasingly difficult. The ongoing emergence of new DMD therapies with different mechanisms of action and efficacy and safety profiles contributes to this complexity, as do the continuing scientific advances in MRI parameters and biomarkers research. These changes impact not only ongoing management, but patient counseling and long-term DMD decision-making as well, making MS management increasingly difficult.

Individualizing Therapy and Optimizing Treatments in MS will provide clinicians with education on the latest advances in the diagnosis and management of MS, so they can improve the care they provide to their MS patients.

TARGET AUDIENCE

This activity is intended for neurologists, MS specialists, primary care physicians, and other health care professionals who manage patients with multiple sclerosis.

EDUCATIONAL OBJECTIVES

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

- Incorporate the latest MRI criteria and other prognostic measures to improve diagnosis and initiate DMD therapy earlier in the course of MS
- Assess the mechanisms of action and efficacy and safety profiles of current and emerging DMD therapies to develop individualized MS therapies that optimize adherence and improve patient outcomes
- Utilize evidence from recent diagnostic and prognostic biomarker studies to improve monitoring of disease activity and response to DMD therapy in MS

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 *AMA PRA Category 1 creditTM*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

SPECIAL SERVICES



Event staff will be glad to assist you with any special needs.

FEE AND RECEIVING CME CREDIT

There is no fee for this educational activity. To receive CME credit the participant must:

- Participate in this one-hour-long program in its entirety;
- Sign in / sign out on the sheet provided by the host coordinator;
- Complete the evaluation forms;
- Return the evaluation forms to the host coordinator.

DISCLOSURE/CONFLICT OF INTEREST STATEMENT

The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.

The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

DISCLOSURES

Faculty Speaker

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Faculty Speaker, MD: *Consultant:* Pharma Name; *Clinical Investigator:* Pharma Name

Steering Committee

The steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Suhayl Dhib-Jalbut, MD: *Consultant:* Bristol-Myers Squibb, Genentech, Genzyme, Mallinckrodt, Merck, Serono, Teva; *Research:* Biogen, Teva; *Spouse is a Consultant for:* AbbVie and *Co-founder of:* Mentinova

Aaron E. Miller, MD: *Consultant:* Accordant Health Services, Acorda, Alkermes, Biogen Idec, Caremark, EMD Serono (Merck Serono), Genentech, Genzyme/Sanofi-Aventis, GlaxoSmithKline, Mallinckrodt (Questcor), Novartis, Roche, Teva; *Research:* Biogen Idec, Genentech, Genzyme, Mallinckrodt (Questcor), Novartis, Roche, Sanofi-Aventis; *Speaker's Bureau:* Biogen Idec

Non-faculty Content Contributors

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Matthew Horn, MD; Blair St. Amand; Jay Katz, CHCP; Lindsay Scott, PT, DPT, ATC:
Nothing to disclose

FDA DISCLOSURE

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

STEERING COMMITTEE



SUHAYL DHIB-JALBUT, MD

Professor and Chairman, Departments of Neurology
Rutgers-New Jersey Medical School and -Robert Wood Johnson Medical School
Chief, Neurology Service
Robert Wood Johnson University Hospital
New Brunswick, NJ

Suhayl Dhib-Jalbut, MD is Professor and Chairman of the Departments of Neurology at Rutgers-New Jersey Medical School and Rutgers-Robert Wood Johnson (RWJ) Medical School, and also serves as Director of the RWJ Center for Multiple Sclerosis (MS). Dr. Dhib-Jalbut currently serves as President of the Americas Committee for Treatment and Research in MS (ACTRIMS).

Dr. Dhib-Jalbut graduated Alpha-Omega-Alpha from the American University of Beirut in Lebanon and completed his training in neuroimmunology and multiple sclerosis at the National Institutes of Health.

Dr. Dhib-Jalbut's research, funded by the NIH, the National MS Society, and industry sources, includes how MS therapies work, biomarkers of treatment response in MS, and neuroprotective gene therapy. Dr. Dhib-Jalbut has published more than 130 manuscripts in the scientific literature. He served on several national and international scientific committees including Chairmanship of the Scientific Committee for the World Congress on MS in 2008 and presided over the same congress in Boston in 2014.

Dr. Dhib-Jalbut has received several awards and recognitions, including the Norman H. Edelman Clinical Science Mentoring Award at Rutgers, the Musical Moments Medical Excellence Award by the National MS Society, the Edward III Award for Excellence in Clinical Research, and the NJ Foundation Excellence in Research Award.

STEERING COMMITTEE



AARON E. MILLER, MD

Professor of Neurology
Icahn School of Medicine at Mount Sinai
Medical Director
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, NY


Aaron E. Miller, MD is Professor of Neurology at the Icahn School of Medicine at Mount Sinai and Medical Director at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis. He is widely recognized for his preeminence as an MS clinician and thought-leader.

Dr. Miller graduated from Brandeis University in 1964 and received his medical doctorate from New York University School of Medicine in 1968. Following his residency in neurology at the Albert Einstein College of Medicine, he received additional postdoctoral training in neurovirology and immunology at the Johns Hopkins University School of Hygiene and Public Health and at Einstein. During this time, he was the recipient of a fellowship from the National MS Society. In 2004, Dr. Miller assumed the position of Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Mount Sinai School of Medicine. For 23 years prior, he headed the Division of Neurology at Maimonides Medical Center in Brooklyn, NY, where he continues to serve as Co-director of the MS Care Center.

Dr. Miller has been the Chief Medical Officer of the National MS Society (NMSS) since October 2001 and served as Chairman of the National Medical Advisory Board of the NMSS from 2001-2009. He has been a member of the NMSS Board of Directors since 2003, and was Chairman of the Clinical Advisory Committee of the New York Chapter of the NMSS from 1991-2004. He was also Chairman of the Professional Education Committee of the NMSS and is a Past President of the Consortium of MS Centers. He was the first Chairman of the Multiple Sclerosis Section of the American Academy of Neurology (AAN), and has participated in numerous clinical trials of new treatments for MS.

Dr. Miller is a member of the AAN Board of Directors, and was Editor of *Continuum*, their bimonthly continuing education publication, from 2003-2012 and continues to serve as Editor of *Continuum Audio*. Dr. Miller has served as the Principal Investigator for many clinical trials in MS and has been a member of many data and safety monitoring boards. He is the co-author of 2 books on MS and related disorders and has published many peer-reviewed articles and book chapters.

FACULTY



SPEAKER'S NAME, DEGREES

Title

Affiliation

City, STATE

Speaker's biography goes here.